| Business Summary | | Miravant
Medical
Technologies
is
developing
light-activated
drugs
and
associated
devices
for
a
medical
procedure
called
photodynamic
therapy.
The
Company
has
branded
its
proprietary
version
of
photodynamic
therapy
as
PhotoPoint.
PhotoPoint
therapy
integrates
the
Company's
drugs
with
its
light-producing
components
and
light-delivery
devices
to
achieve
a
photochemical
effect
on
targeted
diseased
cells
and
blood
vessels.
PhotoPoint
therapy
is
a
platform
technology
that
has
the
potential
to
be
a
safe
and
effective
treatment
for
a
broad
range
of
diseases,
including
those
in
ophthalmology,
oncology,
cardiology
and
dermatology.
The
Company
is
conducting
a
variety
of
pre-clinical
studies
in
each
of
these
areas
and
is
supporting
human
clinical
trials
in
ophthalmology
with
its
lead
drug
candidate,
SnET2
(tin
ethyl
etiopurpurin). | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MRVT
is
engaged
in
the
research
and
development
of
drugs
and
medical
device
products
for
use
in
photodynamic
therapy,
a
procedure
which
uses
light-activated
drugs
to
achieve
selective
photochemical
destruction
of
diseased
cells.
For
the
six
months
ended
6/30/01,
revenues
fell
12%
to
$2.6
million.
Net
loss
fell
37%
to
$6.8
million.
Results
reflect
lower
license
revenues
due
to
the
completion
of
certain
preclinical
studies,
offset
by
lower
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Gary Kledzik, Ph.D., 50 Chairman
and CEO | $325K | David Mai, 55 Pres | 250K | John Philpott, 39 CFO,
Treasurer | 175K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|